-
Product Insights
NewNet Present Value Model: Argenx SE’s Empasiprubart
Empower your strategies with our Net Present Value Model: Argenx SE's Empasiprubart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – Argenx SE
Argenx SE (argenx) is an immunology company that focuses on the development of human antibodies. The company is primarily developing products for autoimmune diseases. Its key product includes VYVGART, a neonatal Fc receptor blocker, which is used to treat generalized myasthenia gravis in adults which are anti-acetylcholine receptor (AChR) antibody positive. The company’s pipeline products include Efgartigimod, ARGX-117, Cusatuzumab, ARGX-118, ARGX-119 and ARGX-120. argenx in partnership with Leo Pharma, AgoMab, AbbVie and Staten has been licensed to develop products such...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Empasiprubart in Delayed Graft Function (DGF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Empasiprubart in Delayed Graft Function (DGF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Empasiprubart in Delayed Graft Function (DGF) Drug Details: ARGX-117...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Empasiprubart in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Empasiprubart in Dermatomyositis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Empasiprubart in Dermatomyositis Drug Details: ARGX-117 (PRO-02) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Efgartigimod Alfa + Hyaluronidase (human Recombinant)) in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Efgartigimod Alfa + Hyaluronidase (human Recombinant)) in Graves' Ophthalmopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Efgartigimod Alfa + Hyaluronidase (human Recombinant))...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Efgartigimod Alfa + Hyaluronidase (human Recombinant)) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Efgartigimod Alfa + Hyaluronidase (human Recombinant)) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Efgartigimod Alfa +...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Antibody-Mediated Rejection (AMR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Antibody-Mediated Rejection (AMR) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Antibody-Mediated Rejection (AMR) Drug Details: Efgartigimod...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Idiopathic Inflammatory Myopathy (IIM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Idiopathic Inflammatory Myopathy (IIM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Idiopathic Inflammatory Myopathy (IIM) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Tachycardia (Tachyarrhythmias)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Tachycardia (Tachyarrhythmias) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Tachycardia (Tachyarrhythmias) Drug Details: Efgartigimod alfa-fcab (Vyvgart)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Immune Mediated Necrotizing Myopathy (IMNM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Immune Mediated Necrotizing Myopathy (IMNM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Immune Mediated Necrotizing Myopathy...